BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Intech Investment Management LLC

Intech Investment Management LLC increased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 47.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 65,647 shares of the company’s stock after purchasing an additional 21,024 shares during the period. Intech Investment Management LLC’s holdings in BridgeBio Pharma were worth $1,801,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of BBIO. Janus Henderson Group PLC boosted its stake in shares of BridgeBio Pharma by 11.7% in the third quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company’s stock worth $122,658,000 after acquiring an additional 505,481 shares during the last quarter. Erste Asset Management GmbH purchased a new stake in shares of BridgeBio Pharma during the third quarter worth $3,497,000. Massachusetts Financial Services Co. MA raised its position in shares of BridgeBio Pharma by 23.3% in the third quarter. Massachusetts Financial Services Co. MA now owns 737,367 shares of the company’s stock valued at $18,773,000 after buying an additional 139,104 shares during the last quarter. Exome Asset Management LLC lifted its stake in shares of BridgeBio Pharma by 167.4% in the third quarter. Exome Asset Management LLC now owns 211,000 shares of the company’s stock worth $5,372,000 after buying an additional 132,093 shares in the last quarter. Finally, Barclays PLC boosted its position in BridgeBio Pharma by 31.9% during the third quarter. Barclays PLC now owns 545,008 shares of the company’s stock worth $13,876,000 after acquiring an additional 131,743 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors and hedge funds.

BridgeBio Pharma Trading Up 0.5 %

BridgeBio Pharma stock opened at $33.91 on Friday. The firm has a market capitalization of $6.45 billion, a P/E ratio of -11.90 and a beta of 1.07. The stock’s fifty day simple moving average is $33.96 and its 200-day simple moving average is $29.03. BridgeBio Pharma, Inc. has a twelve month low of $21.62 and a twelve month high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The firm had revenue of $5.88 million during the quarter, compared to analyst estimates of $4.04 million. Sell-side analysts predict that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Analyst Ratings Changes

BBIO has been the topic of several recent research reports. Cantor Fitzgerald restated an “overweight” rating and set a $95.00 target price on shares of BridgeBio Pharma in a report on Friday, February 21st. Evercore ISI upped their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a report on Monday, December 23rd. Scotiabank lifted their price target on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Friday, February 21st. Bank of America upped their price objective on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Finally, Citigroup lifted their target price on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $51.55.

Insider Transactions at BridgeBio Pharma

In related news, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $32.96, for a total transaction of $197,760,000.00. Following the transaction, the insider now owns 19,260,971 shares in the company, valued at $634,841,604.16. This trade represents a 23.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Brian C. Stephenson sold 68,000 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total value of $2,467,720.00. Following the transaction, the chief financial officer now directly owns 93,758 shares in the company, valued at approximately $3,402,477.82. This trade represents a 42.04 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 9,579,739 shares of company stock valued at $323,171,901. Insiders own 24.66% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.